6UGW

Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a C-centered orthorhombic crystal form, Lot A

Summary for 6UGW

• Entry DOI: 10.2210/pdb6ugw/pdb
• Descriptor: PF-06438179/GP1111 Fc, beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ZINC ION, ... (5 entities in total)
• Functional Keywords: antibody, biologic, biosimilar, infliximab, fragment crystallizable, immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 1
• Total formula weight: 30038.82

Authors

Mayclin, S.J.,Edwards, T.E. (deposition date: 2019-09-26, release date: 2019-11-13, Last modification date: 2024-10-16)

Primary citation

Lerch, T.F.,Sharpe, P.,Mayclin, S.J.,Edwards, T.E.,Polleck, S.,Rouse, J.C.,Zou, Q.,Conlon, H.D.
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar.
BioDrugs, 34:77-87, 2020

PubMed Abstract: Higher-order structure (HOS) assessment is an important component of biosimilarity evaluations. While established spectroscopic methods are routinely used to characterize structure and evaluate similarity, the addition of X-ray crystallographic analysis to these biophysical methods enables orthogonal elucidation of HOS at higher resolution.

PubMed: 31650490
DOI: 10.1007/s40259-019-00390-1

Experimental method

X-RAY DIFFRACTION (2 Å)